Abstract:KEYWORDS: Drug design and development (DDD) is a lengthy and time-consuming process. The process can take up to 14–15 years, and the cost ranges from US 2,826 million (2019 estimate), and these costs keep rising [ Citation 1 ]. For several decades, computers have played a key role in DDD. The application of an extensive group of computational or in silico tools are referred to as computer-aided drug design (CADD), which have been used in academia and industry for several years [ Citation 2 ]. CADD is an interdisciplinary field and has become one of the pillars in the pharmaceutical discovery pipelines. Current significant technological advances that are transforming CADD into computationally-driven drug discovery (CDDD) include but are not limited to [ Citation 3 ]: large (10 6 –10 7 ) compound libraries in stock; ultra-large (10 10 –10 15 ) on-demand, and generative virtual libraries (10 23 –10 60 ); advances in structure-based and artificial intelligence (AI)-based virtual screening of the large and ultra-large spaces; de novo design; free energy perturbation and AI-based QSAR/QSPR modeling to enhance potency and selectivity; data-driven computational tools to predict absorption, distribution, metabolism, excretion, and bioactivity, and toxicology. The latter predictions are now routinely used in multiparameter hit-to-lead optimization. However, any computational model – regardless of its accuracy and applicability – will never ensure that all the predictions are correct. Strictly speaking, exact prediction of an experimental value is not possible as any experimental determination also has a degree of uncertainty. Computational predictions require experimental validation with appropriate and robust in vitro and in vivo assays. In turn, the experimental data can be fed back into the models to improve the quality [ Citation 3 , Citation 4 ]. In addition, as discussed in Section 2, AI plays a key role in synthesis planning and computational approaches that are used in the wet lab as part of the DDD automatization process.

What is the plausibility that all drugs will be designed by computers by the end of the decade?

Entering the era of computationally driven drug development

Past, Present, and Future Perspectives on Computer-Aided Drug Design Methodologies

Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis

The New Era of Drug Discovery: The Power of Computer-aided Drug Design (CADD)

Artificial Intelligence in De novo Drug Design: Are We Still There?

Current perspectives and trend of computer-aided drug design: a review and bibliometric analysis

A Guide to In Silico Drug Design

Computer-Aided Drug Design towards New Psychotropic and Neurological Drugs

Retro Drug Design: From Target Properties to Molecular Structures

Big data and artificial intelligence (AI) methodologies for computer-aided drug design (CADD)

Harnessing Computational Modeling for Efficient Drug Design Strategies

The Millennia-Long Development of Drugs Associated with the 80-Year-Old Artificial Intelligence Story: The Therapeutic Big Bang?

Recent Trends in Drug Design and Discovery

Artificial intelligence facilitates drug design in the big data era

Research on the application of computer in drug design

Exploring the Artificial Intelligence and Machine Learning Models in the Context of Drug Design Difficulties and Future Potential for the Pharmaceutical Sectors

Research on targeted drug design based on computer technology

Computational approaches streamlining drug discovery

Bench to bedside: The ambitious goal of transducing medicinal chemistry from the lab to the clinic

COMPUTER AIDED DRUG DESIGN: AN OVERVIEW